8-K: Tivic Health Reports Fiscal Year 2023 Results: Revenue Declines, Cost-Cutting Measures Implemented

Tivic Health reported a decrease in revenue for 2023, alongside cost-cutting measures and strategic investments in new product development.

Summary

• Tivic Health's revenue for 2023 was $1.2 million, a decrease of 36% compared to $1.8 million in 2022.
• The decline in revenue was primarily due to a 52% decrease in ClearUP unit sales, partially offset by a 46% increase in average selling price per unit.
• Cost of sales decreased by 42% to $889 thousand in 2023, down from $1.5 million in 2022, due to lower unit sales, but included $172 thousand in write-offs related to older inventory.
• Gross profit increased slightly to $330 thousand in 2023 from $299 thousand in 2022.
• Research and development expenses remained relatively stable at approximately $1.7 million for both 2023 and 2022.
• Sales and marketing expenses decreased to $2.1 million in 2023 from $2.8 million in 2022, due to reduced advertising and agency costs.
• General and administrative expenses decreased to $4.8 million in 2023 from $5.9 million in 2022, primarily due to lower legal and professional fees.
• The company's net loss for 2023 was $8.2 million, an improvement from the $10.1 million loss in 2022.
• Tivic raised approximately $3.6 million through a public offering in February 2023 and $4.3 million through a series of offerings between July and August 2023.
• A 1-for-100 reverse stock split was implemented in August 2023, and the company regained compliance with NASDAQ's minimum bid price requirement in September 2023.
• As of December 31, 2023, Tivic had $3.4 million in cash and cash equivalents and maintained a no-debt balance sheet.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company has made progress in reducing costs and improving its net loss, the significant decline in revenue is concerning. The strategic investments and clinical programs are positive, but the overall sentiment is neutral to slightly negative due to the revenue challenges.

Positives

• The company's net loss decreased by $1.9 million year-over-year, indicating improved financial performance.
• Cost of sales decreased by 42% due to lower unit sales and cost-cutting measures.
• Sales and marketing expenses were reduced by $667 thousand, reflecting improved marketing efficiency.
• General and administrative expenses decreased by $1.1 million, showing effective overhead cost reduction.
• The company successfully raised $7.9 million through public offerings.
• Tivic completed enrollment for a pilot clinical study of a proprietary approach to non-invasive vagus nerve stimulation.
• Tivic was recognized as one of the World's Most Innovative Companies by Fast Company.

Negatives

• Revenue decreased by 36% year-over-year, primarily due to a significant drop in ClearUP unit sales.
• The company experienced a net loss of $8.2 million for the year, although this was an improvement from the previous year.
• The company incurred $172 thousand in costs related to write-offs or reserves on old inventory and components.

Risks

• The company's reliance on direct-to-consumer sales, which accounted for over 90% of sales in 2023, may pose a risk if this channel underperforms.
• The company's ability to raise additional capital on favorable terms is uncertain.
• The company's future performance is subject to market, economic, and supply chain conditions.
• The company's financial condition could be impacted by unexpected costs, charges, or expenses.
• The company's new product development and clinical programs may not yield the expected results.

Future Outlook

The company is focused on streamlining its commercial business, defining new opportunities for value creation, and investing in clinical programs, including vagus nerve stimulation and opiate-use reduction following sinus and facial surgeries. The company expects to file its Annual Report on Form 10-K on March 25, 2024.

Management Comments

• Jennifer Ernst, CEO of Tivic, stated that 2023 was a year for both streamlining the commercial business and defining new opportunities for value creation.
• She noted that the company has taken substantial steps towards improving financial health by implementing a new pricing structure, reducing costs, improving marketing efficiency, and decreasing headcount.
• She also mentioned strategic investments in clinical programs to create new paths for value creation for shareholders.

Industry Context

Tivic operates in the bioelectronic medicine sector, which is gaining traction as a non-invasive alternative to traditional pharmaceutical treatments. The company's focus on vagus nerve stimulation aligns with growing interest in this area for treating various conditions. The company's recognition by Fast Company and Global Health & Pharma highlights its innovative approach in the medical device industry.

Comparison to Industry Standards

• Tivic's revenue decline of 36% contrasts with the growth seen in some areas of the medical device industry, particularly in the bioelectronic medicine sector, where some companies are experiencing rapid expansion.
• Companies like ElectroCore, which also focuses on non-invasive vagus nerve stimulation, have reported varying financial results, with some quarters showing growth and others facing challenges, indicating the competitive and evolving nature of this market.
• Compared to larger medical device companies with established product lines, Tivic's revenue is relatively small, reflecting its early stage of commercialization and the challenges of scaling a new technology.
• The company's cost-cutting measures are in line with industry trends for smaller companies seeking to improve profitability and manage cash flow, especially in the face of revenue challenges.
• Tivic's focus on direct-to-consumer sales is a common strategy for smaller medical device companies, but it also presents challenges in terms of marketing and distribution compared to companies with established relationships with healthcare providers.

Stakeholder Impact

• Shareholders may be concerned about the revenue decline but encouraged by the cost-cutting measures and reduced net loss.
• Employees may be affected by the headcount reduction implemented by the company.
• Customers may benefit from the new pricing structure and the company's continued focus on product development.
• Suppliers may be impacted by the company's efforts to reduce costs of goods.
• Creditors may be reassured by the company's no-debt balance sheet.

Next Steps

• The company will file its Annual Report on Form 10-K with the Securities and Exchange Commission on March 25, 2024.
• Management will host a webcast/conference call on March 25, 2024, to discuss the company's year-end 2023 financial results and provide a business update.
• The company will continue to focus on its clinical programs, including vagus nerve stimulation and opiate-use reduction following sinus and facial surgeries.

Key Dates

Keywords

bioelectronic medicine, ClearUP, vagus nerve stimulation, sinus pain relief, financial results, revenue, cost reduction, clinical study, medical device, public offering